Skip to content

Warby Parker

US · WRBY #2446 by market cap Listed 2021
25.31 -0.92 -3.51%
Live - 5344 symbols - heartbeat 29s ago · 2026-10-08 07:28
Pre-market 24.84 -1.86%
After-hours 25.31 0.00%
Overnight 25.25 -0.24%
Market cap
3.13B
P/B
7.98
EPS
0.01
Reader sentiment Are you bullish or bearish on WRBY?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 8.27 Expensive vs history 74th percentile
5-year average 6.52 · #45 of 51 in Medical Instruments & Supplies
P/E ratio 437.17 Expensive vs history 90th percentile
5-year average 193.05 · forward 83.68 · #27 of 27 in Medical Instruments & Supplies
P/S ratio 3.56 Expensive vs history 70th percentile
5-year average 3.63 · forward 3.08 · #34 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Warby Parker (WRBY) 3.13B 421.83 7.98 0.00%
Intuitive Surgical (ISRG) 146.44B 47.54 8.06 0.00%
Becton Dickinson & Co (BDX) 49.07B 54.43 2.01 2.33%
ResMed (RMD) 31.78B 21.67 4.83 1.06%
Medline (MDLN) 31.10B 67.27 2.69 0.00%
Alcon (ALC) 30.45B 48.09 1.41 0.56%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value22.75 Economic moatNone UncertaintyHigh

Trading 10.1% above Morningstar's fair value estimate.

Fair value

Warby Parker Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 17% premium over our quantitative fair value estimate of $22.75 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to EBITDA ratio of 31.9, which ranks in the top 20% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be expensive.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.0%, a core component of profitability, falls in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 07:28:40 · For reference only, not investment advice and not tailored to your situation.